1. No category

Final Program
Thursday, 26 March, 2015
14:00
Registration
18:30
Welcome Reception
Friday, 27 March, 2015
08:45 - 09:00 Opening Ceremony
Greetings by:
Hermann Haller, Germany, Conference Co-Chair
Talma Rosenthal, Israel, Conference Co-Chair
09:00 - 10:30 Plenary Session 1
Chairs: A.J. Manolis, Greece; R. Zimlichman, Israel
09:00
Targeting the Endothelium – Strategies in Combination Therapy
(Invited Lecture)
H. Haller, Dept. of Nephrology, Hannover Medical School, Hannover, Germany
09:30
Combination Therapy in Hypertension: What is Suggested by
Randomized Controlled Trials? (Invited Lecture)
A. Zanchetti, Istituto Auxologico Italiano and University of Milan, Italy
10:00
Vascular Health as a Focus in the Treatment of Hypertension
(Invited Lecture)
R. Touyz, University of Glasgow, UK
10:30 - 11:00 Coffee Break and Posters Viewing
11:00 - 13:00 Plenary Session 2
Chairs: M. Bursztyn, Israel; A. Zanchetti, Italy
11:00
Resistant Hypertension: Novel Treatment Option (Invited Lecture)
R. Dechend, Experimental and Clincal Research Center, Charité-Campus
Buch and Helios Clinic Berlin Buch, Germany
11:30
Hypertension and Atrial Fibrillation (Invited Lecture)
A.J. Manolis, Asklepeion General Hospital, Athens, Greece
12:00
Early Combination Therapy in Type 2 Diabetes (Invited Lecture)
C. Bianchi, Department of Clinical and Experimental Medicine, University of
Pisa, Italy
12:30
Primary Hyperaldosteronism: Is the Epidemic Over? (Invited Lecture)
N. Stern, Tel Aviv Sourasky Medical Center, Israel
13:00 -14:00 Lunch Break
Friday, 27 March, 2015 (cont.)
14:00 - 15:00
Plenary Session 3: Free Paper Session
Chairs: C. Bianchi, Italy; K. Raafat, Lebanon
14:00
Combination Phyto-Metformin Therapy to Diabetes and Related
Complications
K. Raafat, Pharmaceutical Sciences, Beirut Arab University, Lebanon
14:20
Hormonal Contraception Related with Diabetes Mellitus Type 2
S. Lindawati, Health Department, Community Health Center, Jakarta,
Indonesia
14:40
An Audit of Diabetes Self-Management Education Programs in South
Africa
L. Dube, Université Catholique de Louvain, Louvain, Belgium
15:00 - 15:30 Coffee Break and Posters Viewing
15:30 - 17:00 Plenary Session 4: Free Paper Session
I. Kuźmiuk, Poland;
15:30
Combination Therapy in Lipid Disorders Patients: Past, Present and
Future (Invited Lecture)
M. Banach, Medical University of Lodz, Lodz, Poland
16:00
Napping: Is it Bad for you? (Invited Lecture)
M. Bursztyn, Department of Medicine, Hypertension Unit, Hadassah-Hebrew
University Medical Center, Mount-Scopus, Jerusalem, Israel
16:30
Poster Presentations
5 minute short presentations
Saturday, 28 March, 2015
09:00 - 10:00 Plenary Session 5
Chairs: D. Raev, Bulgaria; K. Stoschitzky, Austria
09:00
Fixed Combination: Innovation That Stood the Test of Time
(Invited Lecture)
T. Rosenthal, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv,
Israel
09:30
What is New in the Management of Blood Pressure in Chronic
Kidney Disease? (Invited Lecture)
E. Holtzman, The Chaim Sheba Medical Center, Tel Hashomer, Israel
10:00 - 10:30 Coffee Break and Posters Viewing
10:30 - 12:30 Plenary Session 6: Free Papers
Chairs: L. Cheng, Australia; N. Stern, Israel
10:30
The Fixed Combination in the Antihypertensive Treatment in Patients
after Renal Transplantation
I. Kuźmiuk, Dept. of Nephrology, Transplantology and Internal Medicine
Medical University of Gdańsk, Poland
10:50
Central Administration of DHA and DHAderivative Regulates
Peripheral Energy Homeostasis by Increasing Central Leptin
Sensitivity in Mice
L. Cheng, School of Medicine, University of Wollongong, Wollongong,
NSW, Australia
11:10
Chronic Fatigue Syndrome vs Depressive Disease: Blood Pressure
is The Key - Midodrine and Sertraline Solution?
J.A. Meireles-Brandão, Medicina, Faculdade de Medicina do Porto and
Starmedica.Clinica, Porto, Portugal
11:30
Blood Pressure, Heart Rate, or the Rate Pressure Product: What is
the Best Predictor of Outcome in Arterial Hypertension?
K. Stoschitzky, Abteilung für Kardiologie, Medizinische Universitätsklinik
Graz, Graz, Austria
11:50
High Dose of Fixed Combination of Olmesartan Plus Amlodipine
Allows a Good Compliance in Diabetics Receiving Multiple Drugs
V. Spagnuolo, Unit of Internal Medicine, Annunziata Hospital, Italy
12:10 - 13:00 Poster Presentations - 5 minute short presentations
13:00 – 14:00 Lunch Break
14:00 - 16:40 Plenary Session 7
Chairs:; P.M. Nilsson, Sweden; T. Unger
14:00
Combined Interference with the RAS in Cardiometabolic Disease:
AT1 Receptor Blockade and AT2 Receptor Stimulation in One Pill?
(Invited Lecture)
T. Unger, CARIM – School for Cardiovascular Diseases, Maastricht University,
The Netherlands
14:30
The Differential Effect of Atherosclerosis on End Organ Damage in
Patients with Hypertension and CVRF’sWhy some Patients Develop MI and others Stroke? Mechanisms and
Treatment Considerations (Invited Lecture)
R. Zimlichman, Sackler Faculty of Medicine, Tel-Aviv University,
The E. Wolfson Medical Center, Holon, Israel
15:00
Fixed Combination Treatment for Glycaemic Control in Type 2 Diabetes:
What is the Difference? (Invited Lecture)
P.M. Nilsson, Dept. of Clinical Sciences, Lund University, Sweden
15:30
Coffee Break and Posters Viewing
16:00 - 16:40 Plenary Session 8
Chairs: E. Holtzman, Israel; O. Odunukan, USA
16:00
Late Onset of Gingival Hyperplasia in a Patient Undergoing Fixed-Dose
Combination Antihypertensive Therapy
C. Podoleanu, Dept. of Cardiology, University of Medicine and Pharmacy of
Tirgu Mures, Romania
16:20
Higher Survival in Hypertension Patients on Fixed Drug Combination
Therapies
O. Odunukan, Cardiovascular Diseases, Mayo Clinic, Jacksonville, FL, USA
16:40
Adjourn
Sunday, 29 March, 2015
09:00 - 10:30 Plenary Session 9
09:00
Panel Discussion
Panelists:
H. Haller, Dept. of Nephrology, Hannover Medical School, Hannover, Germany
C. Lippert, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
R. Touyz, University of Glasgow, UK
10:30 - 11:00 Coffee Break and Posters Viewing
11:00 - 13:15 Plenary Session 10
11:00
Pros and Cons on Polypill
M. Banach, Medical University of Lodz, Lodz, Poland
T. Unger, CARIM – School for Cardiovascular Diseases, Maastricht University,
The Netherlands
11:40
Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin
Fixed Dose Combination Compared to Separate Tablets
C. Lippert, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
12:00
Complementary Mechanisms of Action of Dapagliflozin and Metformin
A. Romanovschi, Global Medical Affairs, AstraZeneca, UK
12:20
Use of FDC in Initial Antihypertensive Therapy in Bulgaria
D. Raev, Clinic of Internal Medicine, University Hospital "St. Anna", Bulgaria
12:40
Investigation of Brain-Derived Neurotrophic Factor (BDNF) Gene
Expression in Hypothalamus of Obese Rats: Modulation by Omega-3
Fatty Acids
S. Abdel-Maksoud, German University in Cairo, Faculty of Pharmacy and
Biotechnology, Egypt
13:00
Best Poster Award
POSTER PRESENTATIONS
The Health Benefit of Consuming a Cinnamon Supplement for 8 Weeks in Overweight
Women
T.S. Aldayel, Dept. of Nutritional Sciences, School of Biosciences and Medicine, Faculty of
Health and Medical Sciences,University of Surrey, UK
Endogenous Angiotensin-(1-7)/MAS Receptor/NO and Downstream Modulation of TNF:
Are Involved Cardioprotective Effects of Pacing Postconditioning
Fawzi Babiker, Physiology, Kuwait University, Kuwait
Significant Correlation of ET-1 Biomarker and Renal Endothelial Dysfunction, Real
Option for Efficient HTA Treatment in Diabetic Type 2 Patients
Benereta Hoxha, Dept. of Nephrology, Central Polyclinic, Albania
Combined Supplementation with Quercetin and Myricetin Ameliorates Hyperglycemia
and Inflammation in Mice Fed a High-Fat, High-Sucrose Diet
J-I. Kim, Smart Food and Drugs, Inje University, Gimhae, Gyungnam, South Korea
The Possible Cardiovascular Effect of Medic SheosTM on Subjective and
Hemodynamic Parameters in Diabetic and/or PVD Patients
E. Klainman, Pulmonary Institute, Kaplan MC, Physiological Unit, Rehovot, Israel
Impact of Lifestyle on CVD Risk Factors in the Young Adults
M. Koziarska-Rosciszewska, Nephrology, Hypertension and Family Medicine, Medical
University of Lodz, Poland
Features Fixed Combination in Management of Hypertensive Patients with Diabetes,
Dyslipidemia and Subclinical Hypothyroidism
Alla Logvinenko, Dept. of Essential Hypertension, National Scientific Center “M.D. Strazhesko
Institute of Cardiology of NAMS of Ukraine”, Ukraine
Atherogenic Potential and Insulin Resistance of Subclinical Hypothyroidism and Ways
of His Correction
Alla Logvinenko, Dept. of Essential Hypertension, National Scientific Center “M.D. Strazhesko
Institute of Cardiology of NAMS of Ukraine”, Ukraine
Analytical Methods for Quantitative Determination of Fixed Dose Combinations with
Selective Beta-Blockers in Biological Fluids
S.C. Mahu, Dept. of Toxicology, Faculty of Pharmacy, University of Medicine and Pharmacy
"Grigore T. Popa"- Iași, Romania
Fixed Combination Sitagliptine-Met Formin (Janumet®) in the Treatment of Type 2
Diabetic Patients with High Cardiovascular Risk
S. Nedogoda, I. Barykina, A. Salasyuk, Dept. of Therapy and Endocrinology FUV, Volgograd
State Medical University, Russia
Fixed Combination Vildagliptine-Me-Formin (Galvusmet®) in the Treatment of
Overweight Patients with Metabolic Syndrome
S. Nedogoda, I. Barykina, A. Salasyuk, Department of Therapy and Endocrinology FUV,
Volgograd State Medical University, Russia
Estimation of Application of Fixed Combinations: Angiotensin Receptor II Antagonists:
Calcium Channel Blockers for Hypertension Treatment
D. Obreshkova, Dept. of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University
Sofia, Bulgaria
Assessment of the Impact of Hypolipidemic Therapy on the relationship between Lipid
Parameters and Inflammatory Markers in Non-Diabetic Obese Patients
M. Stępień, Dept. of Nephrology, Hypertension and Family Medicine, Medical University of
Lodz, Poland
A Case of Diabetes who Experienced Cross-Sensitization of Skin Complication
between Lpragliflozin and Dapagliflozin
Y.Suzuki, Diabetes Department, HDC Atlas Clinic, Tokyo, Japan
The First Case of Type 2 Diabetes who Received SGLT2 Inhibitor Therapy after Kidney
Transplantation
Y.Suzuki, Diabetes Department, HDC Atlas Clinic, Tokyo, Japan
A Case of Type 2 Diabetes who Improved Carpal Tunnel Syndrome after Taking SGLT2
Inhibitors
Y.Suzuki, Diabetes Department, HDC Atlas Clinic, Tokyo, Japan
A Case of Diabetes who Experienced Improvement of Skin Complication after the
Change from Luseogliflozin to Dapagliflozin
Y.Suzuki, Diabetes Department, HDC Atlas Clinic, Tokyo, Japan
Compensatory Overeating (COE) could be a Problem of Diabetes Diet Education after
Sodium-Glucose Co-Transporter 2 Inhibitor Treatment
Y.Suzuki, Diabetes Department, HDC Atlas Clinic, Tokyo, Japan
Gain of Muscle Strength in Mitochondrial Diabetes Treated with SGLT2 Inhibitor
Y.Suzuki, Diabetes Department, HDC Atlas Clinic, Tokyo, Japan
Urinary Angiotensinogen as a Marker of Intrarenal Angiotensin II Activity in
Adolescents with Primary Hypertension
A. Wasilewska, Dept. of Pediatrics and Nephrology, Medical University of Białystok, Poland